# Nanjing Iaso Biotherapeutics Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nanjing-iaso-biotherapeutics-co

- Industry: Biotechnology
- Headquarters: Nanjing, China
- Website: www.iasobio.com
- Total disclosed funding: $242M
- Latest round: Series C (Jan 18, 2023)
- Investors on record: 13

## About

Based in Nanjing, China, and founded in 2017 by founder Brian K. Hall and its CEO, Dr. Wen Wang, Nanjing Iaso Biotherapeutics Co., Ltd. operates as a biotechnology company that focuses on developing cell therapies for the treatment of cancer. In September 2021, Nanjing Iaso Biotherapeutics Co., Ltd. raised USD 108 million in series C funding led by CDH Baifu Capital, with CCB International, CNCB (Hong Kong) Investment, CoStone Venture Capital, Everbright Capital Investment, Plaisance Capital, and GL Ventures. The company's CEO, Dr. Wang Wen, received his bachelor's degree in clinical medicine from Anhui Medical University and worked as an orthopedic resident and attending physician at Shanghai Integrated Chinese and Western Medicine Hospital.

Nanjing Iaso Biotherapeutics Co., Ltd. is developing a clinical-stage pipeline of multiple autologous and allogeneic CAR-T and biologics product candidates. This includes a portfolio of 8 novel pipeline products, as well as IASO’s asset, CT103A, an innovative anti-BCMA CAR-T cell therapy understudy for relapsed/refractory (R/R) multiple myeloma (RRMM). In addition. The company developed CD19/CD22 dual-targeted chimeric antigen receptor (CAR)-T cell therapy, which can be used for the treatment of CD19/CD22-positive relapsed/refractory B-cell non-Hodgkin's lymphoma (r/r B-NHL) and relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL).

## Funding rounds

- Series C, Jan 18, 2023, $74M — Efung Capital, Shanghai Guoxin Venture Capital Investment, Nanjing Dajiangbei Guozi Investment Group, HosenCare Brothers, Hongcheng Investment Management, Shanghai Waigaoqiao Free Trade Zone Group Co., Ltd.
- Series C, Sep 16, 2021, $108M — Plaisance Capital, CoStone Capital, Everbright Capital, CNCB (Hong Kong) Investment, CDH Baifu Capital, CCB International, GL Ventures
- Series B, Mar 23, 2020, $60M — GL Ventures

## Investors

- GL Ventures (https://capitalatlas.ai/funds/gl-ventures) — Series B, Series C
- Plaisance Capital — Series C
- CoStone Capital (https://capitalatlas.ai/funds/costone-capital) — Series C
- Everbright Capital (https://capitalatlas.ai/funds/everbright-capital) — Series C
- CNCB (Hong Kong) Investment (https://capitalatlas.ai/funds/cncb-hong-kong-investment) — Series C
- CDH Baifu Capital (https://capitalatlas.ai/funds/cdh-baifu-capital) — Series C
- CCB International (https://capitalatlas.ai/funds/ccb-international) — Series C
- Efung Capital (https://capitalatlas.ai/funds/efung-capital) — Series C
- Shanghai Guoxin Venture Capital Investment — Series C
- Nanjing Dajiangbei Guozi Investment Group — Series C
- HosenCare Brothers (https://capitalatlas.ai/funds/hosencare-brothers) — Series C
- Hongcheng Investment Management (https://capitalatlas.ai/funds/hongcheng-investment-management) — Series C
- Shanghai Waigaoqiao Free Trade Zone Group Co., Ltd. — Series C